Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $25.00 for the company and are forecasting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Accelerate Diagnostics an industry rank of 155 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 24th.
Shares of Accelerate Diagnostics (NASDAQ:AXDX) opened at 23.45 on Wednesday. The firm has a 50-day moving average price of $21.48 and a 200-day moving average price of $23.16. Accelerate Diagnostics has a one year low of $10.87 and a one year high of $28.50. The stock’s market cap is $1.21 billion.
In related news, insider Lawrence Mehren sold 400,068 shares of the stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $19.00, for a total transaction of $7,601,292.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Matthew Strobeck acquired 8,000 shares of the company’s stock in a transaction that occurred on Monday, January 9th. The shares were acquired at an average price of $19.00 per share, for a total transaction of $152,000.00. Following the purchase, the director now owns 2,045,560 shares of the company’s stock, valued at $38,865,640. The disclosure for this purchase can be found here. Company insiders own 51.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in Accelerate Diagnostics by 8.7% in the fourth quarter. State Street Corp now owns 416,027 shares of the company’s stock valued at $8,634,000 after buying an additional 33,401 shares during the period. Cutter & CO Brokerage Inc. purchased a new stake in shares of Accelerate Diagnostics during the fourth quarter valued at approximately $579,000. Russell Investments Group Ltd. purchased a new stake in shares of Accelerate Diagnostics during the fourth quarter valued at approximately $282,000. Geneva Advisors LLC raised its stake in shares of Accelerate Diagnostics by 64.1% in the third quarter. Geneva Advisors LLC now owns 44,605 shares of the company’s stock valued at $1,216,000 after buying an additional 17,425 shares during the last quarter. Finally, Advisor Group Inc. purchased a new stake in shares of Accelerate Diagnostics during the third quarter valued at approximately $109,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zacks-accelerate-diagnostics-inc-axdx-given-25-00-average-target-price-by-brokerages/1655391.html
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.